Bayer
Business & Industry
- Pfizer advances today's cancer care and tomorrow's potential breakthroughs at ESMO
- An open letter from the Chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi
- Sanofi and Cheplapharm to create new strategic partnership in mature medicines
- AstraZeneca expands company’s $100m+ commitment to advance youth health equity in more than 60 countries
- Pfizer and Valneva's Lyme disease vaccine candidate Marketing Authorization Application validated by European Medicines Agency
Research & Development
- Can AI find drugs to fight infection?
- How interferon changes cancerous blood stem cells
- New US Medicare pricing policies could reshape global pharmaceutical markets
- Experimental study points to systemic sclerosis treatment
- New method causes cancer cells to burn out
- Tiny molecular rings open new ways for designing better medicines
- Mini-tumors reveal new drug combinations for liver cancer
Conferences & Events
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
- CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
- FDA approves first in class targeted therapy for metastatic pancreatic cancer
- FDA approves first drug of its kind for polycythemia vera, a rare blood disorder
- FDA expands artificial intelligence capabilities with agentic AI deployment
- FDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
- FDA approves new treatment for hemophilia A or B